ASCO 2017: Avelumab and Axitinib in Untreated Renal Cell Carcinoma
As a front-line treatment regimen, combining the immune checkpoint inhibitor avelumab and the vascular endothelial growth factor (VEGF) receptor inhibitor axitinib resulted in encouraging early antitumor activity in treatment-naive patients with advanced renal cell carcinoma, according to data from the phase Ib JAVELIN trial, presented by Toni K. Choueiri, MD, and colleagues, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4504).
The study enrolled 55 patients to receive intravenous avelumab at 10 mg/kg every 2 weeks plus axitinib at 5 mg orally twice a day. A total of 54 patients received the combination treatment, with 1 patient never receiving avelumab. The confirmed objective response rate was 54.5%, based on 2 complete and 28 partial responses. Progression-free and overall survival data are not yet mature.
The investigators found the safety profile of the drug combination to be consistent with the safety of the agents administered as monotherapy. “These data support the ongoing phase III trial [JAVELIN Renal 1010] investigating the efficacy and safety of avelumab plus axitinib in untreated metastatic clear-cell advanced renal cell carcinoma,” said Dr. Choueiri, Clinical Director at the Lank Center for Genitourinary Oncology and senior physician at Dana-Farber Cancer Institute.